Phil Taylor on Muck Rack

Phil Taylor

Verified
Birmingham
As seen in: Pharmaphorum, Sports Illustrated, EIN News, Fierce Pharma, Fierce Biotech, Nuvo, PMLiVE, Securing Industry

Get in touch with Phil

Contact Phil, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Phil Taylor’s Biography

Read Full Bio →

Healthcare hack (cough)

Articles

Scribe Therapeutics joins the IPO queue

|
By Phil Taylor Verified
| Pharmaphorum Verified
News Scribe's president and CEO, Benjamin Oakes Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq, in what is being seen as a test of the appetite among investors for earlier-stage drug developers.
Open in Who Shared Issue with article?

Trial of Bundibugyo Ebola drugs starts in DRC

|
By Phil Taylor Verified
| Pharmaphorum Verified
Patients are being recruited into a clinical trial of two potential therapies for the Bundibugyo species of Ebola in the Democratic Republic of the Congo (DRC), according to the World Health Organization (WHO).
Open in Who Shared Issue with article?

Respiratory biotech Celea raises $180m, and other financings

|
By Phil Taylor Verified
| Pharmaphorum Verified
This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum. PureTech's Celea eyes phase 3 for IPF drug after $180m round Armed with an impressive $180 million financing, Celea Therapeutics has hatched a plan to start an ambitious phase 3 trial of its lead drug, a modified derivative of Roche's Esbriet (pirfenidone), in patients with idiopathic pulmonary fibrosis.
Open in Who Shared Issue with article?
See all 11,061 licensed articles (11,073 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified